CancerVax

Known as: C-VAX 
CancerVax is an allogenic polyvalent vaccine composed of irradiated but viable cells from three melanoma cell lines and Bacille Calmette-Guerin (BCG… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2012
012319982012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
CancerVax and the John Wayne Cancer Institute are co-developing Biotechnology Tumor antigen Canvaxin, a vaccine containing over… (More)
Is this relevant?
2004
2004
Background: Canvaxin polyvalent specific active immunotherapeutic (CancerVax Corp., Carlsbad, CA) is a minimally toxic adjuvant… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2003
2003
PURPOSE A therapeutic polyvalent cancer vaccine (Canvaxin vaccine; CancerVax Corp, Carlsbad, CA) induces antibodies to a… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE The curative effect of surgery in certain patients with metastatic melanoma suggests the presence of endogenous antitumor… (More)
Is this relevant?
2002
2002
PURPOSE Although the improved overall survival (OS) of patients who receive Canvaxin (CancerVax Corp, Carlsbad, CA) polyvalent… (More)
Is this relevant?
2002
2002
We have observed prolonged survival in patients undergoing vaccine reinduction after resection of recurrent metastatic melanoma… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2001
2001
Background: The immunogenicity of the polyvalent tumor cell vaccine CancerVax has been correlated with the survival of patients… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2001
2001
Introduction: TA90 is a tumor-associated 90-kD glycoprotein antigen expressed on most melanoma cells, including those of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
1998
1998
Background: Case control studies have demonstrated that administration of CancerVax, a polyvalent melanoma cell vaccine (PMCV… (More)
  • figure 2
  • table 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1998
1998
PURPOSE The mechanisms that underlie the clinical efficacy of melanoma vaccines are not well understood. We hypothesized that the… (More)
Is this relevant?